Ritlecitinib is the only Janus kinase inhibitor licensed for alopecia areata in children, and only from age 12. Everything else in paediatric use — abrocitinib, baricitinib, deuruxolitinib, ruxolitinib, tofacitinib, upadacitinib — is off-label, and this review sets out what the accumulated case series and clinical experience actually support on selection, dosing and monitoring.
Two threads are worth acting on. Children with concomitant atopic or autoimmune disease, raised IgE or eosinophilia appear to do particularly well, which turns the comorbidity into part of the drug choice rather than a complication of it. And early-onset, extensive disease is an argument for considering systemic treatment sooner rather than exhausting topicals first.
The evidence base is heterogeneous reports with inconsistent outcome measures, not trials. That is a reason to be explicit with families about what is licensed, what is not, and what the monitoring schedule will be — not a reason to withhold treatment from a child with total scalp loss.
- Say plainly which drug is licensed for the child's age and which is off-label, and document the discussion.
- Let atopic or autoimmune comorbidity, raised IgE and eosinophilia inform which agent you choose.
- Consider systemic therapy earlier in early-onset extensive disease rather than after a topical sequence.
- Set the monitoring schedule — bloods, lipids, infection screening — before the first prescription.
- Involve the school and address the psychosocial burden at the same visit; it is the outcome families care about.
Why it matters
It moves paediatric alopecia areata from a condition watched and waited on to one with a treatment decision to make.
Don't overread it
This is a clinical review of heterogeneous reports, not trial evidence, for every agent except ritlecitinib.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for dermatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free